{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"43.8","upperLimit":"61.3","value":"52.6"},{"groupId":"OG001","lowerLimit":"3.4","upperLimit":"18.7","value":"9.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"133"},{"groupId":"OG001","value":"66"}],"units":"Participants"}],"description":"Disease Control Rate (DCR) was defined as the percentage of subjects whose best response was Complete Response (CR: disappearance of all clinical and radiological evidence of tumor (both target and non-target).), Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum, no unequivocal progression of existing non-target lesions, and no appearance of new lesions.), or Stable Disease (SD: steady state of disease. Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, no unequivocal progression of existing non-target lesions, and no appearance of new lesions.) according to RECIST v1.1 criteria. SD had to be maintained for at least 12 weeks from the first demonstration of that rating. Results are based on central evaluation.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received Regorafenib (Stivarga) 160 mg (4 x 40 mg tablets) per os once daily, 3 weeks on therapy followed by 1 week off therapy to comprise a cycle of 4 weeks","id":"OG000","title":"Regorafenib (Stivarga, BAY73-4506)"},{"description":"Participants received matching Placebo tablets per os once daily, 3 weeks on therapy followed by 1 week off therapy to comprise a cycle of 4 weeks","id":"OG001","title":"Placebo"}],"paramType":"NUMBER","populationDescription":"Full Analysis Set (FAS)","reportingStatus":"POSTED","timeFrame":"From randomization of the first subject until date of database cutoff (26 Jan 2012); study duration approximately 1 year","title":"Disease Control Rate (DCR)","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}